Market Moves

Tencent takes a minority stake in Hangzhou brain-chip developer Nanochap Electronics

A Chinese company building a brain implant to restore sight now has Tencent on its cap table. Tencent has taken a minority equity stake in Hangzhou-based Nanochap Electronics Co., Ltd., disclosed through a 28 May 2026 business registration filing showing Shanghai Qishan Investment (a Tencent subsidiary) added as a new shareholder. Nanochap’s registered capital after the transaction stands at RMB 16.8853 million (approximately $2.35 million). Exact stake size and dollar value of Tencent’s investment have not been publicly disclosed. The investment is the second in a six-week window in which Chinese big tech firms have taken equity positions in domestic BCI hardware companies, following Alibaba’s lead investment in Shanghai-based StairMed in March 2026 (which Tencent also joined).

What Nanochap actually does

Nanochap Electronics is headquartered in Hangzhou, with research centres in Melbourne, Australia, and Ho Chi Minh City. The company was founded in 2014 to develop a retinal implant and describes its business as the research, manufacture and commercialisation of brain-computer interfaces and biochips. Its lead product is E-BCI, a 320-channel retinal implant for people blinded by retinal disease. On 6 May 2026 Nanochap announced a RMB 300 million strategic round, co-led by Legend Capital and an unnamed industrial investor, to fund clinical trials, and on 19 May surgeons at Zhejiang Provincial People’s Hospital implanted the device in a first patient.

Nanochap also sells nerve stimulation chips, biosensing chips and EEG detection chips, which it markets for consumer health, rehabilitation and research products such as massage, beauty-care and smart-home devices.

The pattern across Chinese big-tech BCI investment

The Nanochap investment lands inside a broader pattern of Chinese big-tech equity participation in domestic BCI hardware. In March 2026, Alibaba led a 500 million RMB (approximately $72.7 million) funding round into Shanghai-based StairMed Technology, with Tencent participating as an existing investor. StairMed is a clinical-stage invasive BCI company developing a 256-channel wireless implant. The combined Alibaba and Tencent activity across StairMed and Nanochap shows two of the three largest Chinese tech firms now hold equity in Chinese brain-implant developers.

The structural signal is that Chinese big tech is treating BCI as a strategic category requiring early-stage equity exposure rather than a wait-and-see commercial opportunity. The Tencent and Alibaba investments are positioned ahead of the broader Chinese BCI commercial inflection that has compounded across 2026, including Neuracle’s NMPA-approved NEO becoming the world’s first commercial implantable BCI in March 2026, NeuroXess publicly disclosing a 300 character per minute Mandarin LLM decoder this month, and the Beinao-1 combined brain-spine surgery at Xuanwu Hospital reporting one-year follow-up.

Signal: Why it matters

Tencent now holds stakes in two Chinese implant developers at different stages: StairMed, which is developing a 256-channel wireless implant, and Nanochap, which is in clinical trials of a retinal implant for vision restoration. Both positions were taken before either device has regulatory approval.

Forward Radar: What to watch

The first signal is whether Nanochap discloses the size of Tencent’s stake. Business registration filings disclose ownership changes but not investment amount, so the capital Tencent’s vehicle put in remains unconfirmed. The second signal is whether other Chinese big-tech firms (Baidu, Huawei, ByteDance, JD) take similar positions in brain-implant companies in the coming quarters. The current Alibaba and Tencent positions look like a pattern, but two data points are not yet a trend. The third signal is how Nanochap’s retinal implant performs in its clinical trial.

Correction, 4 November 2026: An earlier version of this article described Nanochap as a fabless chip supplier to other brain-implant companies and said it was not a BCI implant company. Nanochap develops its own retinal implant, raised RMB 300 million for its clinical trials on 6 May 2026 and implanted its first patient on 19 May 2026. The article also said its core research team was in Melbourne; its headquarters is in Hangzhou, with a research centre in Melbourne. The descriptions and analysis have been corrected.

Correction, 16 October 2026: An earlier version of this article dated the Alibaba-led StairMed round to April 2026. It was announced on 13 March 2026.

Sources

Weekly BCI Brief in your inbox

Join researchers, investors, and industry leaders who start their day with Inside BCI.